{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:35:44Z","timestamp":1791218144435,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1097\/rhu.0b013e31821d352f","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T12:57:45Z","timestamp":1355749065000},"page":"S44-S49","source":"Crossref","is-referenced-by-count":24,"title":["An Allopurinol-Controlled, Multicenter, Randomized, Open-Label, Parallel Between-Group, Comparative Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Hyperuricemia Including Those With Gout in Japan"],"prefix":"10.1097","volume":"17","author":[{"given":"Kamatani","family":"Naoyuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujimori","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hada","family":"Toshikazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosoya","family":"Tatsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohri","family":"Kenjiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakamura","family":"Toshitaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ueda","family":"Takanori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamamoto","family":"Tetsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamanaka","family":"Hisashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matsuzawa","family":"Yuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210207","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R2-6-20210207","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/15257770802136040","article-title":"Asymptomatic hyperuricemia: impact of ultrasonography.","volume":"27","author":"Puig","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"R4-6-20210207","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.1780080449","article-title":"Correlation among hyperuricemia, hypercholesterolemia, coronary disease and hypertension.","volume":"8","author":"Hall","year":"1965","journal-title":"Arthritis Rheum"},{"key":"R5-6-20210207","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0002-8703(83)90209-0","article-title":"Serum uric acid and coronary heart disease.","volume":"106","author":"Beard","year":"1983","journal-title":"Am Heart J"},{"key":"R6-6-20210207","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/oxfordjournals.aje.a113972","article-title":"Hyperuricemia as a risk factor of coronary heart disease: the Framingham study.","volume":"121","author":"Brand","year":"1985","journal-title":"Am J Epidemiol"},{"key":"R7-6-20210207","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0895-4356(88)90127-8","article-title":"Gout and coronary heart disease: the Framingham study.","volume":"41","author":"Abbott","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"R8-6-20210207","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/jama.1993.03510030102044","article-title":"Uric acid a risk factor for coronary heart disease.","volume":"270","author":"Frohlich","year":"1993","journal-title":"JAMA"},{"key":"R9-6-20210207","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/oxfordjournals.aje.a117479","article-title":"Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I epidemiologic follow-up study.","volume":"141","author":"Freedman","year":"1995","journal-title":"Am J Epidemiol"},{"key":"R10-6-20210207","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2188\/jea.10.403","article-title":"Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers.","volume":"10","author":"Tomita","year":"2000","journal-title":"J Epidemiol"},{"key":"R11-6-20210207","first-page":"437","article-title":"The pharmacology of hypouricemic effect of benzbromarone.","volume":"2","author":"Sinclair","year":"1975","journal-title":"J Rheumatol"},{"key":"R12-6-20210207","first-page":"126","article-title":"Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout.","volume":"76","author":"Rundles","year":"1963","journal-title":"Trans Assoc Am Physicians"},{"key":"R13-6-20210207","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity, description and guidelines for prevention in patients with renal insufficiency.","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R14-6-20210207","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(68)90008-9","article-title":"Renal clearance of oxypurinol, the chief metabolite of allopurinol.","volume":"45","author":"Elion","year":"1968","journal-title":"Am J Med"},{"key":"R15-6-20210207","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0014-2999(93)90201-R","article-title":"Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.","volume":"241","author":"Osada","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"R16-6-20210207","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1074\/jbc.M208307200","article-title":"An extremely potent inhibitor of xanthine oxidoreductase, crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.","volume":"278","author":"Okamoto","year":"2003","journal-title":"J Biol Chem"},{"key":"R17-6-20210207","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0014-2999(93)90033-E","article-title":"Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzee.","volume":"250","author":"Komoriya","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"R18-6-20210207","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase.","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"R19-6-20210207","first-page":"307","article-title":"A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase\/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.","volume":"104","author":"Horiuchi","year":"1999","journal-title":"Res Commun Mol Pathol Pharmacol"},{"issue":"S9","key":"R20-6-20210207","first-page":"S530","article-title":"Phase II dose response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase\/xanthine dehydrogenase inhibitor, for gout and hyperuricemia.","volume":"48","author":"Kamatani","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R21-6-20210207","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"R22-6-20210207","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2710.2005.00670.x","article-title":"Appropriate dosing regimen of allopurinol in Japanese patients.","volume":"30","author":"Takada","year":"2005","journal-title":"J Clin Pharm Ther"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0b013e31821d352f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:55:56Z","timestamp":1620957356000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-201106002-00006"}},"subtitle":["Phase 2 Exploratory Clinical Study"],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e31821d352f","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}